WELCOME TO OUR PARKINSON'S PLACE!

I HAVE PARKINSON'S DISEASES AND THOUGHT IT WOULD BE NICE TO HAVE A PLACE WHERE THE CONTENTS OF UPDATED NEWS IS FOUND IN ONE PLACE. THAT IS WHY I BEGAN THIS BLOG.

I COPY NEWS ARTICLES PERTAINING TO RESEARCH, NEWS AND INFORMATION FOR PARKINSON'S DISEASE, DEMENTIA, THE BRAIN, DEPRESSION AND PARKINSON'S WITH DYSTONIA. I ALSO POST ABOUT FUNDRAISING FOR PARKINSON'S DISEASE AND EVENTS. I TRY TO BE UP-TO-DATE AS POSSIBLE.

I AM NOT RESPONSIBLE FOR IT'S CONTENTS. I AM JUST A COPIER OF INFORMATION SEARCHED ON THE COMPUTER. PLEASE UNDERSTAND THE COPIES ARE JUST THAT, COPIES AND AT TIMES, I AM UNABLE TO ENLARGE THE WORDING OR KEEP IT UNIFORMED AS I WISH. IT IS IMPORTANT TO UNDERSTAND I AM A PERSON WITH PARKINSON'S DISEASE. I HAVE NO MEDICAL EDUCATION,

I JUST WANT TO SHARE WITH YOU WHAT I READ ON THE INTERNET. IT IS UP TO YOU TO DECIDE WHETHER TO READ IT AND TALK IT OVER WITH YOUR DOCTOR. I AM JUST THE COPIER OF DOCUMENTS FROM THE COMPUTER. I DO NOT HAVE PROOF OF FACT OR FICTION OF THE ARTICLE. I ALSO TRY TO PLACE A LINK AT THE BOTTOM OF EACH ARTICLE TO SHOW WHERE I RECEIVED THE INFORMATION SO THAT YOU MAY WANT TO VISIT THEIR SITE.

THIS IS FOR YOU TO READ AND TO ALWAYS KEEP AN OPEN MIND.

PLEASE DISCUSS THIS WITH YOUR DOCTOR, SHOULD YOU HAVE ANY QUESTIONS, OR CONCERNS. NEVER DO ANYTHING WITHOUT TALKING TO YOUR DOCTOR FIRST..

I DO NOT MAKE ANY MONEY FROM THIS WEBSITE. I VOLUNTEER MY TIME TO HELP ALL OF US TO BE INFORMED.

I WILL NOT ACCEPT ANY ADVERTISEMENT OR HEALING POWERS, HEALING FROM HERBS AND ETC. UNLESS IT HAS GONE THROUGH TRIALS AND APPROVED BY FDA. IT WILL GO INTO SPAM.

THIS IS A FREE SITE FOR ALL WITH NO ADVERTISEMENTS

THANK YOU FOR VISITING! TOGETHER WE CAN MAKE A DIFFERENCE!

TRANSLATE

Monday, October 17, 2016

Patent Request Filed for Cannabis-based Treatments for Parkinson’s and Like Diseases

OCTOBER 17, 2016  BY DANIELA SEMEDO, PHD IN NEWS.





Growblox Sciences has filed the first of several likely patent applications for cannabis-based compounds developed by Growblox Life Sciences, its wholly owned subsidiary. The application applies to pharmaceutical-grade mixtures that might be used to treat patients with neurodegeneration, especially those with Parkinson’s disease.
Growblox Life Sciences is focused on researching and developing cannabis-based medicines.  The company uses various technical approaches in plant biology, cultivation, and extraction methods combined with biotechnology.
“Unlike many other companies and researchers who try to reduce the natural complexity in the cannabis plant, we embrace it and it informs our therapeutic mixtures,” Dr. Andrea Small-Howard, chief science officer of Growblox Sciences, said in a press release.
The application covers, specifically, mixtures of cannabis-based compounds that enhance the secretion of the neurotransmitter dopamine, and protect neurons from the mitochondrial-induced free radical damage. Dopamine and neuronal damage are hallmarks in neurodegenerative diseases, such as Parkinson’s, Huntington’s, Alzheimer’s, and Lewy body dementia.
“[W]e test our mixtures in disease systems that include a natural diversity of human cannabis-receptors, not just CB1 and CB2 receptors, which are the only receptors studied by many leading cannabinoid researchers,” Small-Howard said, adding that the mixtures contain “dozens of individually acting agents in order to make effective therapies for different diseases.”
Parkinson’s is an initial treatment focus for the company’s products, because “these patients are in great need of an effective therapeutic treatment,” she added. The proposed Parkinson’s treatment is also attractive because it does not contain relevant amounts of the psychoactive compound in marijuana, delta-9 tetrahydrocannabinol or THC.
The prevalence and incidence of neurodegenerative diseases such as Parkinson’s rise with age, and the number of cases is expected to continue to grow globally in coming decades.
“Our goal is to help the approximately one million patients in the US and ten million world-wide that are living with Parkinson’s disease through our life science research, and we anticipate being able to use the same research processes to create additional innovative therapeutic options for other underserved patient groups in the coming months, ” said John Poss, Growblox Sciences’ CEO.
http://parkinsonsnewstoday.com/2016/10/17/growblox-files-patent-application-for-cannibis-based-treatments-for-parkinsons-neurodegeneration

No comments:

Post a Comment